Clinical Trials
37 trialsNCT03000634 2024-09-05
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
University of Arkansas
Phase 2 Withdrawn
NCT05050305 2024-07-16
Marizomib Central Nervous System (CNS)
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT05820763 2024-07-10
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
Washington University School of Medicine
Phase 2 Withdrawn
NCT06210750 2024-05-17
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT02628704 2023-01-26
SCORE
Karyopharm Therapeutics Inc
Phase 2 Withdrawn
NCT04223661 2022-12-08
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
Indiana University
Phase 2 Withdrawn
NCT03841565 2022-06-15
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT05170789 2022-05-04
ESdRRMM
Tulane University
Phase 2 Withdrawn
NCT04267913 2020-11-20
Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT03608501 2020-01-14
IDEALL
Takeda
Phase 2 Withdrawn
NCT01660997 2019-12-16
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT01647165 2019-12-12
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT03785184 2019-08-28
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
AbbVie
Phase 2 Withdrawn
NCT03232307 2019-08-22
Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03960151 2019-05-22
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT03069950 2019-05-21
Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver
Memorial Sloan Kettering Cancer Center
Phase 2 Withdrawn
NCT03168100 2019-01-28
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
University of Arkansas
Phase 2 Withdrawn
NCT02986451 2018-08-14
Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma
Sun Yat-sen University
Phase 2 Withdrawn
NCT03227432 2018-08-14
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT02985333 2018-05-14
Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Sun Yat-sen University
Phase 2 Withdrawn
NCT00005998 2017-11-29
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT02961816 2017-04-21
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02402725 2017-02-15
UltraDex
Boston Medical Center
Phase 2 Withdrawn
NCT02578121 2017-01-23
UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination
University of Arkansas
Phase 2 Withdrawn
NCT01812720 2016-12-19
CARAMEL 2
Mayo Clinic
Phase 2 Withdrawn
NCT02756663 2016-11-08
PANORAMA-5
Novartis
Phase 2 Withdrawn
NCT01501370 2016-05-10
ZLd_Ld
University of Turin, Italy
Phase 2 Withdrawn
NCT01329289 2016-02-12
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
University of Pittsburgh
Phase 2 Withdrawn
NCT01670084 2015-10-30
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
Mayo Clinic
Phase 2 Withdrawn
NCT00003663 2015-08-19
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
Hoag Memorial Hospital Presbyterian
Phase 2 Withdrawn
NCT00176280 2015-06-18
Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma
University of Kentucky
Phase 2 Withdrawn
NCT02082405 2015-04-24
Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00723658 2015-03-06
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT01055301 2015-03-06
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT02114502 2014-07-11
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00112879 2013-07-10
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00577668 2011-05-03
A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)
University of Arkansas
Phase 2 Withdrawn